États-Unis · Agences & temps réel · PR Newswire

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Publié par PR Newswire · États-Unis il y a 1 h

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

À lire aussi

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

Partager

À lire aussi

Chamberlain University Opens First Utah Campus and 26th Location Nationwide, Expanding Nursing Education in the State with the Fewest Nurses per Capita

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows